Molgora et al. further demonstrated that the inhibition of TREM2, a pro-tumorigenic marker of tumor-associated macrophages, with an anti-TREM2 mAB, substantially increased the performance of anti-PD-1 treatment in a sarcoma mouse model.206 This combination strategy is of particular interest since it effectively targets the immunosuppressive tumor microenvironment and enhances anti-tumor immune responses. Here, TREM2 is linked to sarcoma.